The DOI matches its Crossref record; 363 of the 363 references it cites were found in a registry or an index.
MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy
Open accessAbstract
The potential of alpha-particle emitters to treat cancer has been recognized since the early 1900s. Advances in the targeted delivery of radionuclides and radionuclide conjugation chemistry, and the increased availability of alpha-emitters appropriate for clinical use, have recently led to patient trials of radiopharmaceuticals labeled with alpha-particle emitters. Although alpha-emitters have been studied for many decades, their current use in humans for targeted therapy is an important milestone. The objective of this work is to review those aspects of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance and recommendations for human alpha-particle emitter dosimetry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Although b - and g -radiation are viewed as having a relative biologic ef fi ciency (RBE) of 1.0, other emerging RPTs, particularly those that use radionuclides that emit a -particles, carry much a higher RBE ( 21 ).”
From Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1988) · Elsevier eBooks · doi:10.1016/b978-0-12-780621-1.50005-8 · Cited by 9,077
THE STOPPING AND RANGE OF IONS IN SOLIDS
Ziegler, J. F. (1984) · Elsevier eBooks · doi:10.1016/b978-0-12-780620-4.50007-0 · Cited by 5,892
Recommendations of the International Commission on Radiological Protection
(1961) · Postgraduate Medical Journal · doi:10.1136/pgmj.37.425.168-b · Cited by 5,868
The Stopping and Range of Ions in Matter
Ziegler, J. F., & Biersack, J. P. (1985) · Springer eBooks · doi:10.1007/978-1-4615-8103-1_3 · Cited by 4,360
Radiobiology for the Radiologist.
(1974) · Annals of Internal Medicine · doi:10.7326/0003-4819-80-3-438_1 · Cited by 3,498
The Stopping and Ranges of Ions in Matter
(1980) · Elsevier eBooks · doi:10.1016/c2013-0-02882-4 · Cited by 3,012
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,228
International Commission on Radiological Protection
(1969) · Radiology · doi:10.1148/93.6.1298 · Cited by 2,148
Basic anatomical and physiological data for use in radiological protection: reference values
Valentin, J. (2002) · Annals of the ICRP · doi:10.1016/s0146-6453(03)00002-2 · Cited by 2,024
Report of the task group on reference man
(1979) · Annals of the ICRP · doi:10.1016/0146-6453(79)90123-4 · Cited by 1,715
Research works printed but not linked: 32
- 2005, J Nucl Med., 46, 199S
- 1990, Antibody Immunoconjugates Radiopharm., 4, 85
- 1997, Blood., 90, 2245
- 2006, Cancer Biother Radiopharm., 21, 395
- 2006, Cancer Biother Radiopharm., 21, 396
- 2006, J Nucl Med., 47, 1049
- International Commission on Radiological Protection. Relative Biological Effectiveness (RBE), Quality Factor (Q), and Radiation Weighting Factor (wR). Philadelphia, PA: Elsevier; 2004. ICRP publication 92.
- 1964, Cancer Res., 24, 683
- 1995, J Nucl Med., 36, 259
- 1989, Lancet., 2, 650
- 1997, J Nucl Med., 38, 727
- 2000, J Nucl Med., 41, 941
- 2007, Ann ICRP., 37, 1
- 1994, J Nucl Med., 35, 521
- 1993, J Nucl Med., 34, 1811
- 1988, Cancer Res., 48, 7022
- 1992, J Nucl Med., 33, 2167
- 1994, J Nucl Med., 35, 303
- Fisher DR. The microdosimetry of monoclonal antibodies labeled with alpha emitters. In: Schlafke-Stelson AT, Watson EE, eds. Fourth International Radiopharmaceutical Dosimetry Symposium. Oak Ridge, TN: Oak Ridge Associated Universities; 1986:26–36.
- Kellerer AM. Analysis of patterns of energy deposition: a survey of theoretical relations in microdosimetry. In: Ebert HG, ed. Proceedings of the Second Symposium on Microdosimetry. Brussels, Belgium: Commission of European Communities; 1970:107–134.
- 1997, J Nucl Med., 38, 1923
- 2004, J Nucl Med., 45, 129
- 2001, J Nucl Med., 42, 1216
- 1999, J Nucl Med., 40, 37S
- 1975, J Nucl Med., 16, 248
- 1999, J Nucl Med., 40, 1935
- 2002, J Nucl Med., 43, 97
- 2003, J Nucl Med., 44, 774
- 2005, J Nucl Med., 46, 1171
- 1969, J Nucl Med., 10, 7
- 1999, J Nucl Med., 40, 1947
- Goodhead DT. Talk 23, Alpha Emitters, from Session 6, Effects from Specific Sources of Internal Radiation. Presented at: CERRIE Workshop; July 21–23, 2003; Oxford, U.K.
Cited by
Sorted by citations
Kratochwil, C., Bruchertseifer, F., Giesel, F. L., Weis, M., Verburg, F. A., Mottaghy, F. M., Kopka, K., Apostolidis, C., Haberkorn, U., & Morgenstern, A. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.178673 · Cited by 1,187
Radiopharmaceutical therapy in cancer: clinical advances and challenges
Sgouros, G., Bodei, L., McDevitt, M. R., & Nedrow, J. R. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0073-9 · Cited by 1,032
Self-citationKratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505
Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 418
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth
Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 382
α-Emitters for Radiotherapy: From Basic Radiochemistry to Clinical Studies—Part 1
Poty, S., Francesconi, L. C., McDevitt, M. R., Morris, M. J., & Lewis, J. S. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.186338 · Cited by 279
Self-citationClinical radioimmunotherapy—the role of radiobiology
Pouget, J., Navarro‐Teulon, I., Bardiès, M., Chouin, N., Cartron, G., Pèlegrin, A., & Azria, D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.160 · Cited by 269
Targeted Alpha Therapy, an Emerging Class of Cancer Agents
Targeted Alpha Therapy Working Group, Parker, C. C., Lewington, V. J., Shore, N. D., Kratochwil, C., Levy, M. Y., Lindén, O., Noordzij, W., Park, J. H., & Fred Saad, C. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4044 · Cited by 254
Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The “Hopeful Eight”
Eychenne, R., Chérel, M., Haddad, F., Guérard, F., & Gestin, J. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060906 · Cited by 210
Development of 225Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences
Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202
The Potential and Hurdles of Targeted Alpha Therapy – Clinical Trials and Beyond
Elgqvist, J., Frost, S. H. L., Pouget, J., & Albertsson, P. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2013.00324 · Cited by 198
Dekempeneer, Y., Keyaerts, M., Krasniqi, A., Puttemans, J., Muyldermans, S., Lahoutte, T., D’Huyvetter, M., & Devoogdt, N. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1185412 · Cited by 175
Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
Makvandi, M., Dupis, E., Engle, J. W., Nortier, F. M., Fassbender, M. E., Simon, S., Birnbaum, E. R., Atcher, R. W., John, K. D., Rixe, O., et al. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0550-9 · Cited by 173
Current status of theranostics in prostate cancer
Virgolini, I. J., Decristoforo, C., Haug, A. R., Fanti, S., & Uprimny, C. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3882-2 · Cited by 159
Development of targeted alpha particle therapy for solid tumors.
Tafreshi, N. K., Doligalski, M. L., Tichacek, C. J., Pandya, D. N., Budzevich, M. M., El-Haddad, G., Khushalani, N. I., Moros, E. G., McLaughlin, M. L., Wadas, T. J., et al. (2019) · Molecules · doi:10.3390/molecules24234314 · Cited by 157
Dosimetry of bone metastases in targeted radionuclide therapy with alpha-emitting 223Ra-dichloride
Pacilio, M., Ventroni, G., Vincentis, G. D., Cassano, B., Pellegrini, R., Castro, E. D., Frantellizzi, V., Follacchio, G. A., Garkavaya, T., Lorenzon, L., et al. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3150-2 · Cited by 146
Graf, F., Fahrer, J., Maus, S., Morgenstern, A., Bruchertseifer, F., Venkatachalam, S., Fottner, C., Weber, M. M., Huelsenbeck, J., Schreckenberger, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0088239 · Cited by 143
Targeting PSMA by radioligands in non-prostate disease—current status and future perspectives
Backhaus, P., Noto, B., Avramović, N., Grubert, L. S., Huss, S., Bögemann, M., Stegger, L., Weckesser, M., Schäfers, M. A., & Rahbar, K. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3922-y · Cited by 143
Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches
Thiele, N. A., & Wilson, J. J. (2018) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2018.2494 · Cited by 142
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
Kratochwil, C., Schmidt, K. F., Afshar‐Oromieh, A., Bruchertseifer, F., Rathke, H. G., Morgenstern, A., Haberkorn, U., & Giesel, F. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3817-y · Cited by 142
Meredith, R. F., Torgue, J. J.-C., Azure, M. T., Shen, S., Saddekni, S., Banaga, E., Carlise, R., Bunch, P., Yoder, D., & Alvarez, R. D. (2013) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2013.1531 · Cited by 141
ICRU REPORT 96, Dosimetry-Guided Radiopharmaceutical Therapy
Sgouros, G., Bolch, W. E., Chiti, A., Dewaraja, Y. K., Emfietzoglou, D., Hobbs, R. F., Konijnenberg, M., Gleisner, K. S., Strigari, L., Yen, T., et al. (2021) · Journal of the ICRU · doi:10.1177/14736691211060117 · Cited by 139
Self-citationVariations in Clinical PET/CT Operations: Results of an International Survey of Active PET/CT Users
Beyer, T., Czernin, J., & Freudenberg, L. S. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.079624 · Cited by 136
Radium-223 mechanism of action: implications for use in treatment combinations
Morris, M. J., Corey, E., Guise, T. A., Gulley, J. L., Kelly, W. K., Quinn, D. I., Scholz, A., & Sgouros, G. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0251-x · Cited by 133
Self-citationVaziri, B., Wu, H., Dhawan, A. P., Du, P., & Howell, R. W. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.131037 · Cited by 130
Self-citationCurrent Status of Radiopharmaceutical Therapy
James, S. S., Bednarz, B. P., Benedict, S., Buchsbaum, J. C., Dewaraja, Y. K., Frey, E. C., Hobbs, R. F., Grudzinski, J. J., Roncali, E., Sgouros, G., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.08.035 · Cited by 128
Self-citationdos Santos, J. C., Schäfer, M. K.-H., Bauder‐Wüst, U., Lehnert, W., Leotta, K., Morgenstern, A., Kopka, K., Haberkorn, U., Mier, W., & Kratochwil, C. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4220-z · Cited by 126
Dosimetry of 223Ra-chloride: dose to normal organs and tissues
Laßmann, M., & Noßke, D. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-012-2265-y · Cited by 125
A bone marrow toxicity model for 223 Ra alpha-emitter radiopharmaceutical therapy
Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A.-K., Ramdahl, T., Flux, G. D., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/10/3207 · Cited by 122
Self-citationBismuth-213 for targeted radionuclide therapy: from atom to bedside.
Ahenkorah, S., Cassells, I., Deroose, C. M., Cardinaels, T., Burgoyne, A. R., Bormans, G., Ooms, M., & Cleeren, F. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13050599 · Cited by 120
“3% comes from β-particle emission, which includes the decay of 209Pb [14].”
BackgroundChittenden, S. J., Hindorf, C., Parker, C. C., Lewington, V. J., Pratt, B. E., Johnson, B., & Flux, G. (2015) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.157123 · Cited by 118
Hagemann, U. B., Ellingsen, C., Schuhmacher, J., Kristian, A., Mobergslien, A., Cruciani, V., Wickstroem, K., Schatz, C. A., Kneip, C., Golfier, S., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3476 · Cited by 117
Production, purification and availability of 211At: Near term steps towards global access
Feng, Y., & Zalutsky, M. R. (2021) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2021.05.007 · Cited by 115
Bandekar, A., Zhu, C., Jindal, R., Bruchertseifer, F., Morgenstern, A., & Sofou, S. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.113.125476 · Cited by 112
Antitumor Immunity Induced after α Irradiation
Gorin, J., Ménager, J., Gouard, S., Maurel, C., Guilloux, Y., Faivre-Chauvet, A., Morgenstern, A., Bruchertseifer, F., Chérel, M., Davodeau, F., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.04.002 · Cited by 111
Konijnenberg, M., Herrmann, K., Kobe, C., Verburg, F. A., Hindorf, C., Hustinx, R., & Laßmann, M. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-05038-9 · Cited by 109
Meredith, R. F., Torgue, J. J.-C., Rozgaja, T. A., Banaga, E., Bunch, P., Alvarez, R. D., Straughn, J. M., Dobelbower, M. C., & Lowy, A. M. (2016) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000353 · Cited by 107
Poty, S., Carter, L. M., Mandleywala, K., Membreno, R., Abdel-Atti, D., Ragupathi, A., Scholz, W. W., Zeglis, B. M., & Lewis, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1650 · Cited by 107
Options to meet the future global demand of radionuclides for radionuclide therapy
Das, T., & Pillai, M. R. A. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.09.007 · Cited by 104
Targeted Alpha Therapy: Current Clinical Applications
Liberal, F. D. C. G., O’Sullivan, J. M., McMahon, S. J., & Prise, K. M. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3576 · Cited by 103
Franken, N. A. P., ten Cate, R., Krawczyk, P. M., Stap, J., HAVEMAN, J., Aten, J. A., & Barendsen, G. W. (2011) · Radiation Oncology · doi:10.1186/1748-717x-6-64 · Cited by 99
Pandit-Taskar, N. D., Larson, S. M., & Carrasquillo, J. A. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.112482 · Cited by 97
Normal-Tissue Tolerance to Radiopharmaceutical Therapies, the Knowns and the Unknowns
Wahl, R. L., Sgouros, G., Iravani, A., Jacene, H., Pryma, D., Saboury, B., Capala, J., & Graves, S. A. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262751 · Cited by 95
Self-citationMaguire, W. F., McDevitt, M. R., Smith-Jones, P. M., & Scheinberg, D. A. (2014) · Journal of Nuclear Medicine · doi:10.2967/jnumed.114.138347 · Cited by 93
Self-citationKratochwil, C., Giesel, F. L., Heußel, C. P., Kazdal, D. N., Endris, V., Nientiedt, C., Bruchertseifer, F., Kippenberger, M., Rathke, H. G., Leichsenring, J., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234559 · Cited by 92
ICRP Publication 140: Radiological Protection in Therapy with Radiopharmaceuticals
Yonekura, Y., Mattsson, S., Flux, G., Bolch, W. E., Dauer, L. T., Fisher, D. R., Laßmann, M., Palm, S., Hosono, M., Doruff, M., et al. (2019) · Annals of the ICRP · doi:10.1177/0146645319838665 · Cited by 88
Self-citationHarnessing α -Emitting Radionuclides for Therapy: Radiolabeling Method Review
Yang, H., Wilson, J. J., Orvig, C., Li, Y., Wilbur, D. S., Ramogida, C. F., Radchenko, V., & Schaffer, P. C. (2021) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262687 · Cited by 87
Implementing f-Block Metal Ions in Medicine: Tuning the Size Selectivity of Expanded Macrocycles
Thiele, N. A., Woods, J. J., & Wilson, J. J. (2019) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.9b01277 · Cited by 83
Yang, H., Zhang, C., Yuan, Z., Rodríguez‐Rodríguez, C., Robertson, A. K. H., Radchenko, V., Perron, R., Gendron, D., Causey, P. W., Gao, F., et al. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202002999 · Cited by 81
Radioimmunotherapy with α-Particle-Emitting Radionuclides
Seidl, C. (2014) · Immunotherapy · doi:10.2217/imt.14.16 · Cited by 81
Williams, L. E., DeNardo, G. L., & Meredith, R. F. (2008) · Medical Physics · doi:10.1118/1.2938520 · Cited by 80
Miller, B. W., Frost, S. H. L., Frayo, S. L., Kenoyer, A. L., Santos, E. B., Jones, J. C., Green, D. J., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., et al. (2015) · Medical Physics · doi:10.1118/1.4921997 · Cited by 80
Self-citationPandya, D. N., Hantgan, R. R., Budzevich, M. M., Kock, N. D., Morse, D. L., Batista, I., Mintz, A., Li, K. C., & Wadas, T. J. (2016) · Theranostics · doi:10.7150/thno.14338 · Cited by 80
Tagawa, S. T., Thomas, C., Sartor, A. O., Sun, M., Stangl-Kremser, J., Bissassar, M., Vallabhajosula, S., Castellanos, S. H., Nauseef, J. T., Sternberg, C. N., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.00573 · Cited by 78
Murray, I., Chittenden, S. J., Denis-Bacelar, A. M., Hindorf, C., Parker, C. C., Chua, S. C., & Flux, G. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3744-y · Cited by 78
Boudousq, V., Bobyk, L., Busson, M., Garambois, V., Jarlier, M., Charalambatou, P., Pèlegrin, A., Paillas, S., Chouin, N., Quénet, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069613 · Cited by 76
Dosimetry for Radiopharmaceutical Therapy
Sgouros, G., & Hobbs, R. F. (2014) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2014.03.007 · Cited by 74
Self-citationRadioimmunoconjugates for the Treatment of Cancer
Kraeber‐Bodéré, F., Bodet‐Milin, C., Rousseau, C., Eugène, T., Pallardy, A., Frampas, É., Carlier, T., Ferrer, L., Gaschet, J., Davodeau, F., et al. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.07.004 · Cited by 72
Dauer, L. T., Williamson, M. J., Humm, J. L., O’Donoghue, J. A., Ghani, R., Awadallah, R., Carrasquillo, J. A., Pandit-Taskar, N. D., Aksnes, A.-K., Biggin, C., et al. (2014) · Health Physics · doi:10.1097/hp.0b013e3182a82b37 · Cited by 71
A perspective on the radiopharmaceutical requirements for imaging and therapy of glioblastoma
Bolcaen, J., Kleynhans, J., Nair, S., Verhoeven, J., Goethals, I., Sathekge, M. M., Vandevoorde, C., & Ebenhan, T. (2021) · Theranostics · doi:10.7150/thno.56639 · Cited by 70
Yong, K. J., & Brechbiel, M. W. (2015) · AIMS Medical Science · doi:10.3934/medsci.2015.3.228 · Cited by 70
What is the Role of the Bystander Response in Radionuclide Therapies?
Brady, D., O’Sullivan, J. M., & Prise, K. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00215 · Cited by 70
Advances in targeted alpha therapy for prostate cancer
Vincentis, G. D., Gerritsen, W. R., Gschwend, J. E., Hacker, M., Lewington, V. J., O’Sullivan, J. M., Oya, M., Pacilio, M., Parker, C. C., Shore, N. D., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz270 · Cited by 70
Tumor Immunotargeting Using Innovative Radionuclides
Kraeber‐Bodéré, F., Rousseau, C., Bodet‐Milin, C., Mathieu, C., Guérard, F., Frampas, É., Carlier, T., Chouin, N., Haddad, F., Chatal, J., et al. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms16023932 · Cited by 69
Imaging and dosimetry for radium-223: the potential for personalized treatment
Flux, G. (2017) · British Journal of Radiology · doi:10.1259/bjr.20160748 · Cited by 68
Treatment planning in molecular radiotherapy
Glatting, G., Bardiès, M., & Laßmann, M. (2013) · Zeitschrift für Medizinische Physik · doi:10.1016/j.zemedi.2013.03.005 · Cited by 66
Radioimmunotherapy of Solid Tumors: Searching for the Right Target
Hong, S., & Sgouros, G. (2010) · Current Drug Delivery · doi:10.2174/156720111793663651 · Cited by 64
Self-citationA nephron-based model of the kidneys for macro-to-micro α-particle dosimetry
Hobbs, R. F., Song, H., Huso, D. L., H Sundel, M., & Sgouros, G. (2012) · Physics in Medicine and Biology · doi:10.1088/0031-9155/57/13/4403 · Cited by 61
Self-citationInternal microdosimetry of alpha-emitting radionuclides
HOFMANN, W., Li, W. B., Friedland, W., Miller, B. W., Madas, B. G., Bardiès, M., & Balásházy, I. (2019) · Radiation and Environmental Biophysics · doi:10.1007/s00411-019-00826-w · Cited by 59
203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Li, M., Sagastume, E. A., Lee, D., McAlister, D. R., DeGraffenreid, A. J., Olewine, K. R., Graves, S. A., Copping, R., Mirzadeh, S., Zimmerman, B. E., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200727190423 · Cited by 58
Li, M., Liu, D., Lee, D., Cheng, Y., Baumhover, N. J., Marks, B. M., Sagastume, E. A., Ballas, Z. K., Johnson, F. L., Morris, Z. S., et al. (2021) · Cancers · doi:10.3390/cancers13153676 · Cited by 58
Functionalized TiO2 nanoparticles labelled with 225Ac for targeted alpha radionuclide therapy
Cędrowska, E., Pruszyński, M., Majkowska‐Pilip, A., Męczyńska‐Wielgosz, S., Bruchertseifer, F., Morgenstern, A., & Bilewicz, A. (2018) · Journal of Nanoparticle Research · doi:10.1007/s11051-018-4181-y · Cited by 58
Global experience with PSMA-based alpha therapy in prostate cancer
Sathekge, M. M., Bruchertseifer, F., Vorster, M., Morgenstern, A., & Lawal, I. O. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05434-9 · Cited by 58
Delker, A., Schleske, M., Liubchenko, G., Berg, I., Zacherl, M. J., Brendel, M., Gildehaus, F. J., Rumiantcev, M., Resch, S., Hürkamp, K., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-06092-1 · Cited by 56
Hagemann, U. B., Wickstroem, K., Hammer, S., Bjerke, R. M., Zitzmann-Kolbe, S., Ryan, O. B., Karlsson, J., Scholz, A., Hennekes, H., Mumberg, D., et al. (2020) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2020.3568 · Cited by 56
Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed
Tronchin, S., Forster, J. C., Hickson, K., & Bezak, E. (2022) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac5fe0 · Cited by 55
Microdosimetry for Targeted Alpha Therapy of Cancer
Huang, C., Guatelli, S., Oborn, B. M., & Allen, B. (2012) · Computational and Mathematical Methods in Medicine · doi:10.1155/2012/153212 · Cited by 54
Self-citationGeneral Overview of Radioimmunotherapy of Solid Tumors
Navarro‐Teulon, I., Lozza, C., Pèlegrin, A., Vivès, É., & Pouget, J. (2013) · Immunotherapy · doi:10.2217/imt.13.34 · Cited by 54
In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy
Chan, H. S., de Blois, E., Morgenstern, A., Bruchertseifer, F., de Jong, M., Breeman, W. A. P., & Konijnenberg, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181473 · Cited by 54
From Bench to Bedside—The Bad Berka Experience With First-in-Human Studies
Zhang, J., Singh, A., Kulkarni, H., Schuchardt, C., Müller, D., Wester, H.-J., Μάινα, Θ., Rösch, F., van der Meulen, N. P., Müller, C., et al. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.06.002 · Cited by 54
Aligning physics and physiology: E ngineering antibodies for radionuclide delivery
Tsai, W. K., & Wu, A. M. (2018) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3622 · Cited by 53
Wickstroem, K., Hagemann, U. B., Cruciani, V., Wengner, A. M., Kristian, A., Ellingsen, C., Siemeister, G., Bjerke, R. M., Karlsson, J., Ryan, O. B., et al. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.223701 · Cited by 53
Targeted radio-nuclide therapy of skeletal metastases
Sartor, O. A., Hoskin, P., & Bruland, Ø. S. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.006 · Cited by 52
Garg, R., Allen, K. J. H., Dawicki, W., Geoghegan, E. M., Ludwig, D. L., & Dadachova, E. (2020) · Cancer Medicine · doi:10.1002/cam4.3665 · Cited by 52
Toward the use of single crystal diamond based detector for ion-beam therapy microdosimetry
Verona, C., Magrin, G., Solevi, P., Bandorf, M., Marinelli, M., Stock, M., & Verona-Rinati, G. (2018) · Radiation Measurements · doi:10.1016/j.radmeas.2018.02.001 · Cited by 51
Radiobiological effects of the alpha emitter Ra-223 on tumor cells
Bannik, K., Madas, B. G., Jarzombek, M., Sutter, A. P., Siemeister, G., Mumberg, D., & Zitzmann-Kolbe, S. (2019) · Scientific Reports · doi:10.1038/s41598-019-54884-7 · Cited by 51
Sato, T., Furuta, T., Liu, Y., Naka, S., Nagamori, S., Kanai, Y., & Watabe, T. (2021) · EJNMMI Physics · doi:10.1186/s40658-020-00350-7 · Cited by 51
Branched amphiphilic peptide capsules: Cellular uptake and retention of encapsulated solutes
Sukthankar, P., Avila, L. A., Whitaker, S. K., Iwamoto, T., Morgenstern, A., Apostolidis, C., Liu, K., Hanzlik, R. P., Dadachova, E., & Tomich, J. M. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2014.02.005 · Cited by 50
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
Ruigrok, E. A. M., Tamborino, G., de Blois, E., Roobol, S. J., Verkaik, N. S., Saint‐Hubert, M. D., Konijnenberg, M., van Weerden, W. M., de Jong, M., & Nonnekens, J. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05821-w · Cited by 50
Developments in Combining Targeted Radionuclide Therapies and Immunotherapies for Cancer Treatment
Kerr, C. P., Grudzinski, J. J., Nguyen, T. P., Hernandez, R. T., Weichert, J. P., & Morris, Z. S. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15010128 · Cited by 49
Vascular Targeted Radioimmunotherapy for the Treatment of Glioblastoma
Behling, K., Maguire, W. F., Puebla, J. C. L., Sprinkle, S. R., Ruggiero, A., O’Donoghue, J. A., Gutin, P. H., Scheinberg, D. A., & McDevitt, M. R. (2016) · Journal of Nuclear Medicine · doi:10.2967/jnumed.115.171371 · Cited by 49
Self-citationOmata, A., Kataoka, J., Fujieda, K., Sato, S., Kuriyama, E., Kato, H., Toyoshima, A., Teramoto, T., Ooe, K., Liu, Y., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71019-5 · Cited by 49
Hobbs, R. F., Howell, R. W., Hong, S., Baechler, S., & Sgouros, G. (2014) · Radiation Research · doi:10.1667/rr13483.1 · Cited by 48
Self-citationLi, M., Zhang, X., Quinn, T. P., Lee, D., Liu, D., Kunkel, F., Zimmerman, B. E., McAlister, D. R., Olewein, K., Menda, Y., et al. (2017) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2017.05.006 · Cited by 48
In vitro evaluation of 225Ac‐DOTA‐substance P for targeted alpha therapy of glioblastoma multiforme
Majkowska‐Pilip, A., Rius, M., Bruchertseifer, F., Apostolidis, C., Weis, M., Bonelli, M., Laurenza, M., Królicki, L., & Morgenstern, A. (2018) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13199 · Cited by 48
Predictors and Real-World Use of Prostate-Specific Radioligand Therapy: PSMA and Beyond
Gafita, A., Marcus, C. V., Kostos, L. K., Schuster, D. M., Calais, J., & Hofman, M. S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_350946 · Cited by 47
Dabagian, H., Taghvaee, T., Martorano, P., Martínez, D., Samanta, M., Watkins, C. M., Chai, R., Mansfield, A. J., Graham, T. J. A., Maris, J. M., et al. (2021) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00206 · Cited by 47
Stenberg, V. Y., Larsen, R. H., Ma, L., Peng, Q., Juzenas, P., Bruland, Ø. S., & Juzeniene, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094815 · Cited by 45
Li, M., Baumhover, N. J., Liu, D., Cagle, B. S., Boschetti, F., Paulin, G., Lee, D., Dai, Z., Obot, E. R., Marks, B. M., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020414 · Cited by 44
Targeted alpha anticancer therapies: update and future prospects
Allen, B., Huang, C., & Clarke, R. A. (2014) · Biologics · doi:10.2147/btt.s29947 · Cited by 44
Self-citation
Metadata
- Authors
- Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G.
- Affiliations
- Johns Hopkins University (US)
- Loyola University Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- International Atomic Energy Agency (AT)
- Pacific Northwest National Laboratory (US)
- Vanderbilt University (US)
- Rutgers, The State University of New Jersey (US)
- Texas A&M University (US)
- ORCID
- Venue
- Journal of Nuclear Medicine
- Publisher
- Society of Nuclear Medicine
- Published
- 2010-01-15
- Volume
- 51
- Issue
- 2
- Pages
- 311-328
- ISSN
- 0161-5505 (ISSN-L)
- 2159-662X
- PMC
- PMC5680544
- OpenAlex
- W2018649196
- Cited by
- 552
- References
- 363
- Citations by year
- 2026: 60 · 2025: 58 · 2024: 50 · 2023: 54 · 2022: 50 · 2021: 50 · 2020: 39 · 2019: 34 · 2018: 44 · 2017: 17 · 2016: 21 · 2015: 10 · 2014: 25 · 2013: 11 · 2012: 16
- FWCI
- 9.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Nuclear Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (P50AG005136)
- National Cancer Institute (R01CA109234, R41CA117599, P30CA008748)
- National Institute of Biomedical Imaging and Bioengineering (R01EB001994)
- National Center for Research Resources (R43RR015155)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiopharmaceutical Chemistry and Applications
- Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
- Keywords
- alpha-emitting radionuclides, targeted alpha therapy, radiation biology, dosimetry, radionuclide conjugation, radiopharmaceuticals, cancer therapy
- MeSH terms
- Alpha Particles, Cell Survival, Clinical Trials as Topic, Dose-Response Relationship, Radiation, Female, Humans, Male, Neoplasms, Neoplasms, Radiation-Induced, Pamphlets, Radiation-Protective Agents, Radiobiology, Radioisotopes, Radiotherapy Dosage, Radiotherapy Planning, Computer-Assisted, Relative Biological Effectiveness, Societies, Medical, Cell Death
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
